Title: Addex Q3 2020 Financial Results Conference Call
Date:
Time:
Joining the Conference Call:
1. In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
Dial-In Numbers:
- Switzerland + 41445806522
- UK + 442030092470
- USA + 18774230830
Link for other countries
2. Provide the operator with the Participant PIN Code: 48937768#
Joining the Live Event Online:
- In the 10 minutes prior to the call start time, sign in online by following this Webex Link
- Password : Welcome
About
Press Contacts:
Chief Executive Officer Telephone: +41 22 884 15 55 Email: PR@addextherapeutics.com | Partner, +44 (0)20 7318 2955 msinclair@halsin.com |
Forward Looking Statements:
Certain statements made in this announcement are forward-looking statements including with respect to the anticipated timing of the Company’s clinical trials and the reporting of data therefrom. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including relays resulting from the COVID-19 pandemic and healthcare regulatory considerations. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Title: Addex Q3 2020 Financial Results Conference Call
Date:
Time:
Joining the Conference Call:
1. In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
Dial-In Numbers:
- Switzerland + 41445806522
- UK + 442030092470
- USA + 18774230830
Link for other countries
2. Provide the operator with the Participant PIN Code: 48937768#
Joining the Live Event Online:
- In the 10 minutes prior to the call start time, sign in online by following this Webex Link
- Password : Welcome
About
Press Contacts:
Chief Executive Officer Telephone: +41 22 884 15 55 Email: PR@addextherapeutics.com | Partner, +44 (0)20 7318 2955 msinclair@halsin.com |
Forward Looking Statements:
Certain statements made in this announcement are forward-looking statements including with respect to the anticipated timing of the Company’s clinical trials and the reporting of data therefrom. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including relays resulting from the COVID-19 pandemic and healthcare regulatory considerations. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
© OMX, source